PMID- 15110609
OWN - NLM
STAT- MEDLINE
DCOM- 20041116
LR  - 20181130
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 36
IP  - 3
DP  - 2004 Apr
TI  - In vitro modulation of monocyte chemoattractant protein-1 release in human 
      pancreatic islets.
PG  - 607-8
AB  - Islet transplantation is a new approach to treat type 1 diabetic patients. 
      Despite its great potential and progressively increasing success rate, islet 
      engraftment still represents an unsolved problem. Only part of the transplanted 
      beta-cell mass survives after infusion due to hypoxia and inflammatory reactions, 
      principally mediated by macrophages. We have demonstrated that human islets 
      release monocyte chemoattractant protein-1 (MCP-1), one of the most powerful 
      macrophage chemokines, which may impair the fate of a transplant. In this study 
      we have attempted to modulate in vitro MCP-1 release by human islets. Human 
      islets isolated using the automated method were cultured in CMRL or M199 standard 
      culture media alone or supplemented with (1) two intracellular kinase inhibitors 
      (10 micromol/L RO8220, a protein kinase C inhibitor, and rcAMP 20 micromol/L, a 
      protein kinase A inhibitor) or (2) two antioxidant and cell-protective agents 
      (vitamin E, vitamin B); or (3) immunosuppressive drugs (0.001 to 10 ng/mL 
      cyclosporine, 0.1 to 100 ng/mL rapamycin, 0.1 to 10 ng/mL tacrolimus, 0.001 to 10 
      ng/mL mycophenolate acid). We observed that the only culture condition that 
      significantly decreased MCP-1 in human islets were CMRL (31 +/- 12 in CMRL vs 539 
      +/- 184 pg/mL, in M199, P <.05) or cyclosporine (514 +/- 83 pg/mL in control 
      islet vs 307 +/- 13, 231 +/- 44, 192 +/- 4, 242 +/- 113, 169 +/- 15 pg/mL in 
      islet plus cyclosporine ranging from 0.001 to 10 ng/mL, respectively, P >.05). 
      The capacity of in vitro factors to decrease human islet MCP-1 release suggests 
      strategies to increase the success of islet transplantation.
FAU - Marzorati, S
AU  - Marzorati S
AD  - Surgical Department, San Raffaele Scientific Institute, Milan, Italy.
FAU - Melzi, R
AU  - Melzi R
FAU - Nano, R
AU  - Nano R
FAU - Antonioli, B
AU  - Antonioli B
FAU - Di Carlo, V
AU  - Di Carlo V
FAU - Piemonti, L
AU  - Piemonti L
FAU - Bertuzzi, F
AU  - Bertuzzi F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Culture Media)
RN  - 0 (Cytokines)
SB  - IM
MH  - Cell Culture Techniques/methods
MH  - Cell Separation/methods
MH  - Chemokine CCL2/*metabolism
MH  - Culture Media
MH  - Cytokines/metabolism
MH  - Diabetes Mellitus, Type 1/surgery
MH  - Humans
MH  - Inflammation/prevention & control
MH  - Islets of Langerhans/cytology/*metabolism
MH  - Islets of Langerhans Transplantation
MH  - Macrophages/cytology
MH  - Monocytes/cytology
EDAT- 2004/04/28 05:00
MHDA- 2004/11/17 09:00
CRDT- 2004/04/28 05:00
PHST- 2004/04/28 05:00 [pubmed]
PHST- 2004/11/17 09:00 [medline]
PHST- 2004/04/28 05:00 [entrez]
AID - S0041134504001927 [pii]
AID - 10.1016/j.transproceed.2004.02.048 [doi]
PST - ppublish
SO  - Transplant Proc. 2004 Apr;36(3):607-8. doi: 10.1016/j.transproceed.2004.02.048.